Recent updates on the treatment and management of interstitial lung disease

September 14 marks the second annual ILD Day, which aims to raise awareness of interstitial lung disease.

There are over 200 causes of PID. More than 50,000 cases of PID are diagnosed each year in the United States, with more than 250,000 people living with pulmonary fibrosis and PID, according to the Pulmonary Fibrosis Foundation.

ILD Day takes place on the second Wednesday in September and is a collaboration between the Pulmonary Fibrosis Foundation, Arthritis Foundation, Sarcoidosis Research Foundation, Myositis Association, PF Warriors, The of Scleroderma, the Scleroderma Research Foundation, the Sjögren Foundation and the Wescoe Foundation for Pulmonary Fibrosis.

For ILD Day, the editors at Healio have compiled recent news on interstitial lung disease.

Interstitial lung disease in children linked to high utilization of health services

Childhood PID was associated with high utilization of healthcare services in European countries and the resulting economic burden on healthcare systems, researchers reported in Thorax. Read more

Common environmental exposures in people with pulmonary fibrosis

In people with familial pulmonary fibrosis, environmental exposures are common, vary by sex, and influence CT pattern, time of disease onset, and mortality. Read more

Lung function trajectory ‘varies dramatically’ after PID diagnosis

It is important to consider PID subtypes when applying the criteria for progressive fibrosing PID, the researchers concluded in an analysis published in European Respiratory Journal. Read more

One-third of patients with PID associated with rheumatoid arthritis experience an acute exacerbation

In a new study in Chest, the incidence of acute exacerbations was nearly one-third in patients with PID associated with rheumatoid arthritis. Read more

Concomitant drug load may impact the tolerability of antifibrotic therapy in IPF

According to research published in Annals of the American Thoracic Society. Read more

FDA approves inhaled treprostinil for treatment of PAH, pulmonary hypertension-ILD

ATS Releases New Clinical Practice Guidelines on IPF, Progressive Fibrotic PID

SAN FRANCISCO — A session at the American Thoracic Society’s international conference has highlighted a new clinical practice guideline addressing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults. Read more

Acute exacerbation most common cause of death in patients with rheumatoid arthritis-ILD, IPF

The most common cause of death in patients with rheumatoid arthritis-associated PID as well as those with idiopathic pulmonary fibrosis is acute exacerbation, the researchers reported. Read more